Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Rheumatology
Volume 2013 (2013), Article ID 857694, 4 pages
http://dx.doi.org/10.1155/2013/857694
Case Report

A Case of Subacute Cutaneous Lupus Erythematosus in a Patient with Mixed Connective Tissue Disease: Successful Treatment with Plasmapheresis and Rituximab

1Department of Allergy, Clinical Immunology and Rheumatology, S. Andrea Hospital, Sapienza University of Rome, Italy
2Department of Pathology, S. Andrea Hospital, Sapienza University of Rome, Italy
3Department of Immunohematology and Transfusion Unit, S. Andrea Hospital, Sapienza University of Rome, Italy

Received 4 June 2013; Accepted 26 June 2013

Academic Editors: L.-P. Erwig, M. A. Hunt, and M. Soy

Copyright © 2013 M. Fantò et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. O.-D. Ortega-Hernandez and Y. Shoenfeld, “Mixed connective tissue disease: an overview of clinical manifestations, diagnosis and treatment,” Best Practice and Research, vol. 26, no. 1, pp. 61–72, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Parodi, M. Caproni, C. Cardinali et al., “Clinical, histological and immunopathological features of 58 patients with subacute cutaneous lupus erythematosus. A review by the Italian Group of Immunodermatology,” Dermatology, vol. 200, no. 1, pp. 6–10, 2000. View at Google Scholar · View at Scopus
  3. D. Lipsker, M.-P. Di Cesare, B. Cribier, E. Grosshans, and E. Heid, “The significance of the “dust-like particles” pattern of immunofluorescence. A study of 66 cases,” British Journal of Dermatology, vol. 138, no. 6, pp. 1039–1042, 1998. View at Publisher · View at Google Scholar · View at Scopus
  4. K. M. David-Bajar, S. D. Bennion, J. D. DeSpain, L. E. Golitz, and L. A. Lee, “Clinical, histologic, and immunofluorescent distinctions between subacute cutaneous lupus erythematosus and discoid lupus erythematosus,” Journal of Investigative Dermatology, vol. 99, no. 3, pp. 251–257, 1992. View at Google Scholar · View at Scopus
  5. M. Ramos-Casals, M. J. Soto, M. J. Cuadrado, and M. A. Khamashta, “Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases,” Lupus, vol. 18, no. 9, pp. 767–776, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. Y. Braun-Moscovici, Y. Butbul-Aviel, L. Guralnik et al., “Rituximab: rescue therapy in life-threatening complications or refractory autoimmune diseases: a single center experience,” Rheumatology International, vol. 33, no. 6, pp. 1495–1504, 2013. View at Google Scholar
  7. V. Kieu, T. O'Brien, L.-M. Yap et al., “Refractory subacute cutaneous lupus erythematosus successfully treated with rituximab,” Australasian Journal of Dermatology, vol. 50, no. 3, pp. 202–206, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. V. Smith, Y. Piette, J. T. van Praet et al., “Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement,” The Journal of Rheumatology, vol. 40, pp. 52–57, 2013. View at Google Scholar
  9. D. Daoussis, S. N. Liossis, A. C. Tsamandas et al., “Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis,” Clinical and Experimental Rheumatology, vol. 30, no. 2, supplement 71, pp. S17–S22, 2012. View at Google Scholar
  10. M. Haroon, D. O'Gradaigh, and D. Foley-Nolan, “A case of Raynaud's phenomenon in mixed connective tissue disease responding to rituximab therapy,” Rheumatology, vol. 46, no. 4, pp. 718–719, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Dunkley, M. Green, and A. Gough, “Comment on: a case of Raynaud's phenomenon in mixed connective tissue disease responding to Rituximab therapy—response,” Rheumatology, vol. 46, no. 10, pp. 1628–1629, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Seguchi, Y. Soejima, A. Tateishi et al., “Mixed connective tissue disease with multiple organ damage: successful treatment with plasmapheresis,” Internal Medicine, vol. 39, no. 12, pp. 1119–1122, 2000. View at Google Scholar · View at Scopus
  13. R. M. Crapper, J. P. Dowling, I. R. Mackay, and J. A. Whitworth, “Acute scleroderma in stable mixed connective tissue disease: treatment by plasmapheresis,” Australian and New Zealand Journal of Medicine, vol. 17, no. 3, pp. 327–329, 1987. View at Google Scholar · View at Scopus
  14. J. Rech, S. Kallert, A. J. Hueber, C. Requadt, J. R. Kalden, and H. Schulze-Koops, “Combination of immunoadsorption and CD20 antibody therapy in a patient with mixed connective tissue disease,” Rheumatology, vol. 45, no. 4, pp. 490–491, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Lowe, C. L. Henderson, R. H. Grau, C. B. Hansen, and R. D. Sontheimer, “A systematic review of drug-induced subacute cutaneous lupus erythematosus,” British Journal of Dermatology, vol. 164, no. 3, pp. 465–472, 2011. View at Publisher · View at Google Scholar · View at Scopus